This site uses cookies to ensure the best viewing experience for our readers.
Medical Aesthetic Device Manufacturer InMode Raises $70 Million on Nasdaq IPO

Medical Aesthetic Device Manufacturer InMode Raises $70 Million on Nasdaq IPO

InMode priced its shares at $14, the lower end of its previously suggested range, giving the company a pre-money valuation of $378 million

Golan Hazani  :  2019-08-11T13:48:42..
Israel-based InMode Aesthetic Solutions Ltd. has raised $70 million on its Nasdaq initial public offering Thursday, listing under the ticker INMD. InMode priced its shares at $14, the lower end of its previously suggested range, giving the company a pre-money valuation of $378 million. The company closed 3.3% up on Friday.

InMode develops medical aesthetic devices using radio-frequency energy technology, which can penetrate subdermal fat. The company's main markets are Europe and the U.S., and it is headquartered in Lake Forest, California, with a research and development center in Israel and offices in Canada. For 2018, InMode reported revenues of $100 million, up from $53.5 million in 2017, and a net income of $22.3 million. For the first three months of 2019, the company reported revenues of $30.5 million and a net income of $10.16 million.

InMode was founded as Invasix in 2008 by CEO and chairman Moshe Mizrahi, one of the founders of Israel-based medical device company Syneron Medical Ltd. Prior to the IPO, Mizrahi held a 20.6% stake in InMode. In 2006, Mizrahi co-founded home aesthetics device developer Home Skinovations Ltd., which he previously tried to list three times, the latest earlier this year according to a $300 million company valuation.

Moshe Mizrahi. Photo: Eran Yuppy Cohen Moshe Mizrahi. Photo: Eran Yuppy Cohen Moshe Mizrahi. Photo: Eran Yuppy Cohen

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS